Gillian E. Gadbois
Gillian E. Gadbois has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Fleur M. Ferguson
Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA, 92093, USA
3 shared publications - Andrew J. Tao
Department of Chemistry and Biochemistry University of California San Diego La Jolla CA 92093
2 shared publications Ady Schwarz
Department of Chemistry and Biochemistry
1 shared publication- Benjamin J. Fram
Department of Systems Biology, Harvard Medical School
1 shared publication Bethany C. Berry
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA
1 shared publicationBridget Boyle
Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, 92093, USA
1 shared publication
Latest Publications
- 5 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17339-17349
A Lipid Prodrug Strategy Enhances Targeted Protein Degrader CNS Pharmacokinetics
Targeted protein degraders that recruit the von Hippel–Lindau E3-ligase complex often have poor physicochemical properties, requiring extensive medicinal chemistry optimization prior to use in hypothesis-testing experiments in vivo and with few blood–brain barrier permeable examples disclosed. In this study, we systematically examine a panel of fatty acid promoieties as agents to enhance degrader pharmacokinetics and BBB-exposure. We characterize effects on cellular E3-ligase engagement, cellular BRD4 degradation kinetics, murine plasma stability, and murine blood plasma and brain pharmacokinetics and pharmacodynamics. We identify degrader prodrugs with significantly improved CNS exposure relative to the parent degrader. This led to successful BRD4 degradation in perfused brain samples, demonstrating that fatty acid promoieties can accelerate progress toward proof of principle in vivo experiments for CNS degrader projects.
- 5 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (16) , 17339-17349
A Lipid Prodrug Strategy Enhances Targeted Protein Degrader CNS Pharmacokinetics
Targeted protein degraders that recruit the von Hippel–Lindau E3-ligase complex often have poor physicochemical properties, requiring extensive medicinal chemistry optimization prior to use in hypothesis-testing experiments in vivo and with few blood–brain barrier permeable examples disclosed. In this study, we systematically examine a panel of fatty acid promoieties as agents to enhance degrader pharmacokinetics and BBB-exposure. We characterize effects on cellular E3-ligase engagement, cellular BRD4 degradation kinetics, murine plasma stability, and murine blood plasma and brain pharmacokinetics and pharmacodynamics. We identify degrader prodrugs with significantly improved CNS exposure relative to the parent degrader. This led to successful BRD4 degradation in perfused brain samples, demonstrating that fatty acid promoieties can accelerate progress toward proof of principle in vivo experiments for CNS degrader projects.
- 15 January 2022
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 67, 102114
Targeted protein degradation: Emerging concepts and protein state-specific targeting principles
- 15 January 2022
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 67, 102114
Targeted protein degradation: Emerging concepts and protein state-specific targeting principles
- Open Access
- 1 January 2021
- Published by Elsevier in Current Research in Chemical Biology
- Vol. 1
Synthesis and structure-activity relationships of targeted protein degraders for the understudied kinase NEK9
- 1 January 2021
- Published by Elsevier in Current Research in Chemical Biology
- Vol. 1
Open AccessSynthesis and structure-activity relationships of targeted protein degraders for the understudied kinase NEK9